Social Media Ideas for Amgn:ca

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability o...

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Axsome rises on Auvelity prescription data

AMD: More Room To Fall

GSK: Still One Of My Top Healthcare Picks

GLP-1s: Still Early In The Growth Story

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

XBI: Big Pharma Can Keep The 76% Rally Going

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough

AMD: Gambling With Limited Upside (Downgrade)

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know

AMC Entertainment: Watch The Share Count

Primary Markets Group September 2026 U.S. IPO Update

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months

There are good reasons behind analyst's bullish views of this biotech stock.